KYUNG NAM PHARM.CO.,LTD.
KOSDAQ
₩2,205.00
+8.62%
Delayed · cached 15 min
Fair value analysis
053950
KYUNG NAM PHARM.CO.,LTD.
₩2,205.00
Close used for this calculation
₩2,073.83Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
43/100
Quality radar
Consensus fair value
₩2,073.83
Near FV▼ -5.9% against the close used
Model range ₩82.03 – ₩2,578.80
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩82.03Fair value₩2,073.83Bull₩2,578.80
FairClose
52-week traded range
52W low ₩1,435.0052W high ₩2,210.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
KYUNG NAM PHARM.CO.,LTD. closed at ₩2,205.00, 6.3% above the consensus fair value of ₩2,073.83 drawn from 6 valuation models.
Financial DNA score 43/100 — Average. P/E of 17.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩82.03
-96.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩2,065.11
-6.3%
√(22.5 × EPS × BVPS)
EPS=128.94, BVPS=1470 · outside Graham range (P/E 17.1, P/B 1.5) — asset-light, treat as a rough floor
P/E Fair Value
₩2,578.80
+17.0%
EPS × 20x (sector P/E)
EPS=128.94, Sector P/E=20x
Book Value (P/B)
₩1,207.50
-45.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1470, ROE=8.8%, g=3%, r=10%
Reverse DCF
₩2,205.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 5% | Historical: 0%
Margin of Safety
₩1,181.49
-46.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1575.31, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.